Orthocell (ASX:OCC) said that its nerve repair product, Remplir, was introduced to urologists in Australia for use in "nerve-sparing" robotic-assisted radical prostatectomies, seeking to reduce post-surgical complications caused by peripheral nerve injury, according to a Tuesday Australian bourse filing.

The firm is collecting clinical data on initial patients who underwent radical prostatectomies with Remplir in Australia and will release the clinical data once it is available. Radical prostatectomy is associated with high rates of urinary incontinence and erectile dysfunction after treatment due to damage to the peripheral nerves surrounding the prostate.

The firm will also invest in clinical studies to build evidence and assist medical education initiatives. It believes using Remplir in nerve-sparing robotic-assisted radical prostatectomies represents an opportunity to expand the product's total addressable market.

Its shares jumped 9% in recent trading on Tuesday.